{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T19:59:06Z","timestamp":1791057546702,"version":"4.1.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"13","license":[{"start":{"date-parts":[[2011,9,1]],"date-time":"2011-09-01T00:00:00Z","timestamp":1314835200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2011,9]]},"DOI":"10.1016\/j.ejca.2011.04.019","type":"journal-article","created":{"date-parts":[[2011,5,24]],"date-time":"2011-05-24T02:22:22Z","timestamp":1306203742000},"page":"1955-1961","source":"Crossref","is-referenced-by-count":105,"title":["Angiotensin system inhibitors and outcome of sunitinib treatment in patients with metastatic renal cell carcinoma: A retrospective examination"],"prefix":"10.1016","volume":"47","author":[{"given":"Daniel","family":"Keizman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario A.","family":"Eisenberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Pili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny J.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel S.","family":"Antonarakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Hammers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Carducci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2011.04.019_b0005","doi-asserted-by":"crossref","first-page":"74","DOI":"10.3322\/canjclin.55.2.74","article-title":"Global cancer statistics, 2002","volume":"55","author":"Parkin","year":"2005","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ejca.2011.04.019_b0010","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1007\/s00345-004-0466-0","article-title":"Novel approaches in the therapy of metastatic renal cell carcinoma","volume":"23","author":"Lam","year":"2005","journal-title":"World J Urol"},{"key":"10.1016\/j.ejca.2011.04.019_b0015","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1056\/NEJM199609193351207","article-title":"Renal-cell carcinoma","volume":"335","author":"Motzer","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2011.04.019_b0020","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/S0094-0143(03)00056-9","article-title":"Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease","volume":"30","author":"Janzen","year":"2003","journal-title":"Urol Clin North Am"},{"key":"10.1016\/j.ejca.2011.04.019_b0025","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJMoa065044","article-title":"Sunitinib versus interferon alfa in metastatic renal-cell carcinoma","volume":"356","author":"Motzer","year":"2007","journal-title":"NEJM"},{"key":"10.1016\/j.ejca.2011.04.019_b0030","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1677\/joe.0.1730315","article-title":"Angiotensin II stimulation of Na+\/K+ ATPase activity and cell growth by calcium-independent pathway in MCF-7 breast cancer cells","volume":"173","author":"Muscella","year":"2002","journal-title":"J Endocrinol"},{"key":"10.1016\/j.ejca.2011.04.019_b0035","doi-asserted-by":"crossref","first-page":"H739","DOI":"10.1152\/ajpheart.00656.2001","article-title":"Angiotensin II stimulates migration of retinal microvascular pericytes: involvement of TGF-beta and PDGF-BB","volume":"282","author":"Nadal","year":"2002","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.ejca.2011.04.019_b0040","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0167-4889(97)00129-8","article-title":"Upregulation of vascular endothelial growth factor by angiotensin II in rat heart endothelial cells","volume":"1401","author":"Chua","year":"1998","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.ejca.2011.04.019_b0045","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1681\/ASN.V102245","article-title":"Angiotensin II stimulates the synthesis and secretion of vascular permeability factor\/vascular endothelial growth factor in human mesangial cells","volume":"10","author":"Pupilli","year":"1999","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ejca.2011.04.019_b0050","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1093\/carcin\/bgn171","article-title":"The renin\u2013angiotensin system and malignancy","volume":"29","author":"Aget","year":"2008","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.ejca.2011.04.019_b0055","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1517\/14712598.6.3.243","article-title":"Manipulating the angiotensin system\u2013new approaches to the treatment of solid tumours","volume":"6","author":"Ino","year":"2006","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.ejca.2011.04.019_b0060","doi-asserted-by":"crossref","unstructured":"Kedika R, Patel M, Pena Sahdala HN, et al. Long-term use of angiotensin converting enzyme inhibitors is associated with decreased incidence of advanced adenomatous colon polyps. J Clin Gastroenterol 2010 Aug 6. [Epub ahead of print].","DOI":"10.1097\/MCG.0b013e3181ea1044"},{"key":"10.1016\/j.ejca.2011.04.019_b0065","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1111\/j.1440-1746.2006.04797.x","article-title":"Effect of ACE inhibitors and angiotensin II receptor antagonists in a mouse model of colorectal cancer liver metastases","volume":"22","author":"Neo","year":"2007","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.ejca.2011.04.019_b0070","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1097\/MPA.0b013e3181c314cd","article-title":"Blocking angiotensin II Type 1 receptor triggers apoptotic cell death in human pancreatic cancer cells","volume":"39","author":"Gong","year":"2010","journal-title":"Pancreas"},{"key":"10.1016\/j.ejca.2011.04.019_b0075","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1136\/gut.2009.188961","article-title":"The angiotensin-I-converting enzyme inhibitor enalapril and aspirin delay progression of pancreatic intraepithelial neoplasia and cancer formation in a genetically engineered mouse model of pancreatic cancer","volume":"59","author":"Fendrich","year":"2010","journal-title":"Gut"},{"key":"10.1016\/j.ejca.2011.04.019_b0080","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1007\/s00432-009-0587-3","article-title":"Impact of angiotensin converting enzyme inhibitors and angiotensin II type 1 receptor blockers on survival in patients with advanced non-small-cell lung cancer undergoing first-line platinum-based chemotherapy","volume":"135","author":"Wilop","year":"2009","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.ejca.2011.04.019_b0085","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2011.04.019_b0090","doi-asserted-by":"crossref","unstructured":"Patil S, Figlin RA, Hutson TE, et al. Prognostic factors for progression-free and overall survival with sunitinib targeted therapy and with cytokine as first-line therapy in patients with metastatic renal cell carcinoma. Ann Oncol 2010 Jul 25. [Epub ahead of print].","DOI":"10.1093\/annonc\/mdq342"},{"key":"10.1016\/j.ejca.2011.04.019_b0095","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1002\/cncr.23776","article-title":"Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinoma","volume":"113","author":"Motzer","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2011.04.019_b0130","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1200\/JCO.2007.13.3223","article-title":"Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma","volume":"26","author":"Choueiri","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2011.04.019_b0105","unstructured":"Rini BI, Cohen DP, Lu D, et al. Hypertension (HTN) as a biomarker of efficacy in patients (pts) with metastatic renal cell carcinoma (mRCC) treated with sunitinib. Presented at the 2010 Genitourinary Cancers Symposium [Abstr. 312]."},{"key":"10.1016\/j.ejca.2011.04.019_b0110","doi-asserted-by":"crossref","first-page":"5794","DOI":"10.1200\/JCO.2008.21.4809","article-title":"Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study","volume":"27","author":"Heng","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2011.04.019_b0115","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1200\/JCO.2009.26.7849","article-title":"Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival","volume":"28","author":"Escudier","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2011.04.019_b0120","doi-asserted-by":"crossref","unstructured":"Heng DY, Xie W, Bjarnason GA, et al. Progression-free survival as a predictor of overall survival in metastatic renal cell carcinoma treated with contemporary targeted therapy. Cancer 2010 Nov 18. [Epub ahead of print].","DOI":"10.1002\/cncr.25750"},{"key":"10.1016\/j.ejca.2011.04.019_b0125","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S1470-2045(09)70162-7","article-title":"Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial","volume":"10","author":"Gore","year":"2009","journal-title":"Lancet Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095980491100284X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095980491100284X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,11,24]],"date-time":"2021-11-24T00:06:51Z","timestamp":1637712411000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S095980491100284X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,9]]},"references-count":25,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2011,9]]}},"alternative-id":["S095980491100284X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2011.04.019","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2011,9]]}}}